Browse the evidence

L-aspartate administration led to a significant reduction in body weight, with decreases of 14.5% in HFC diet mice and 8.5% in HFC diet-induced obese mice.

L-aspartate may be considered as a potential treatment for obesity in similar dietary contexts.

Serum or adipose L-aspartate levels were found to be negatively correlated with the severity of obesity in both humans and mice.

Monitoring L-aspartate levels could be relevant in assessing obesity risk.

L-aspartate may serve as a novel endogenous inducer of energy expenditure and suppressor of adipogenesis and lipogenesis along with activation of AMPK.

L-aspartate could be explored as a therapeutic agent for enhancing energy expenditure and reducing fat accumulation.

GLP-1 receptor agonists, particularly semaglutide, may worsen diabetic retinopathy (DR) upon initiation.

Clinicians should monitor diabetic retinopathy closely when initiating GLP-1 receptor agonists.

Glycerol concentration increased by GIP (+13%) and GLP-1/GIP/glucagon receptor triagonist (+28%) in human adipose tissue.

GIP may be a potential target for enhancing fat loss in overweight individuals.

Higher adipose tissue GIP receptor mRNA expression is related to elevated glycerol release after GIP and GLP-1/GIP/glucagon receptor triagonist stimulation.

Increased GIP receptor expression may enhance fat mobilization, suggesting a focus for obesity treatments.

Direct lipolytic effects of GIP exist in human subcutaneous adipose tissue.

GIP could be targeted in therapies aimed at enhancing fat loss.

The PA-GLP1 formulation resulted in an overall reduction in blood glucose levels and reduced weight gain compared to daily injections of semaglutide.

This formulation may be more effective than current daily treatments for diabetes.

The engineered GLP-1 receptor agonist depot offers a more convenient and long-lasting therapeutic option for managing diabetes and treating metabolic disorders.

This approach could simplify treatment regimens for patients with diabetes.

The proportion of GLP-1 RA users without T2DM or obesity rose from approximately 2% in 2020 to over 5% in May 2022.

There is a growing concern regarding the use of GLP-1 RAs in individuals without the approved indications.

Potential misuse of GLP-1 RAs was identified in 2.2% of users.

Monitoring for misuse of GLP-1 RAs is necessary due to the identified percentage of potential misuse.

Obesity has reached an epidemic scope in the United States and is a significant public health concern.

Healthcare practitioners should prioritize addressing obesity as a critical health issue.

Plastic surgery in patients with obesity is associated with higher complication rates before and after weight loss.

Surgeons should be aware of the increased risks when operating on obese patients.

The cost needed to treat for 1% of weight loss with semaglutide and tirzepatide is $1845 and $985, respectively.

Healthcare providers should be aware of the cost implications when prescribing these medications.

Clinical trials of tirzepatide have demonstrated cardiovascular safety in high-risk patients.

Tirzepatide may be considered safe for use in patients at high cardiovascular risk.

The cardiovascular benefits of dual GLP-1/GIP receptor agonists like tirzepatide remain uncertain.

Further research is needed to clarify the cardiovascular benefits of tirzepatide.

Bariatric surgery cannot completely eliminate the possibility of weight regain and inadequate weight loss.

Patients should be informed about the potential for weight regain after surgery.

Higher genetic GLP1R gene expression is associated with a lower risk of kidney disease progression (HR, 0.96; P = .02).

Practitioners may consider the role of GLP1R gene expression in managing kidney disease risk.

Higher GLP1R gene expression is associated with a small reduction in risk of kidney disease progression in fully adjusted models (HR, 0.96; P = .04).

This suggests that monitoring GLP1R gene expression could be relevant in kidney disease management.

GLP-1 reduces glucagon and slows gastric emptying (GE), while GIP increases glucagon and does not alter GE.

Understanding the distinct effects of GLP-1 and GIP can inform treatment strategies for obesity.

Bariatric surgery and endoscopy increase satiation by restricting gastric size and enhance postprandial incretin levels.

Surgical options can be effective for enhancing satiation and managing obesity through hormonal mechanisms.

Changes in lean mass (LM) are not significantly associated with the risk of kidney outcomes (adjusted HR 0.78, 95% CI 0.58-1.06) in participants with overweight/obesity and T2DM.

Practitioners may not need to prioritize lean mass changes for kidney health in T2DM patients.

Nutrients play a multifaceted role in cardiovascular health beyond their impact on cardiac events.

Practitioners should consider the diverse roles of nutrients in promoting cardiovascular health.

Dietary supplements may contribute to CVD risk reduction.

Incorporating dietary supplements may be beneficial for individuals at risk of CVD.